Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Core Insights - Crinetics Pharmaceuticals, Inc. announced the early release of late-breaking abstracts for presentation at the Endocrine Society's annual meeting (ENDO 2024) [1] Group 1: Clinical Studies - The Phase 2, open-label study of atumelnant (CRN04894) in Congenital Adrenal Hyperplasia will present summary data for four subjects, with plans to include additional data from a total of six subjects in cohort 1 and more in cohort 2 at ENDO 2024 [2] - A more comprehensive data set will be shared during the Late-Breaking Poster Presentation session scheduled for June 3, 2024, from 12:00 to 1:30 pm ET [2] Group 2: Company Overview - Crinetics Pharmaceuticals is focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and related tumors [3] - The company is developing paltusotine, an oral somatostatin receptor type 2 (SST2) agonist, currently in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome associated with neuroendocrine tumors [3] - Atumelnant (CRN04894) is an oral ACTH antagonist in Phase 2 studies for congenital adrenal hyperplasia and Cushing's disease [3] - All drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, targeting various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity [3]